SPS 2008 Sponsors

Diamond
($15,000+)

Emerald
($10,000 to $14,999)

Ruby
($6,000 to $9,999)

Opal
($3,000 to $5,999)

Sapphire
(Up to $2,999)

Lewis B. Kinter & Terry Timberlake-Kinter

Distinguished Service Award

Nominations closed at midnight EDT January 14, 2009

This award is to honor an individual who has substantially contributed to the field of Safety Pharmacology.

For a nomination, the following criteria will be considered:

Specific research achievements
Champions of the field
Lifelong contribution to the field
Substantial specific contribution
Visionary direction
Regulatory decisions
Science of the field
Education
Collaboration between industry and academia

The Distinguished Service Award (DSA) will be given every year, although there shall be no obligation or duty to make such award when, in the sole opinion of the committee, there is no qualified nominee.

Nominations
Only Members may nominate although the nominee does not have to be a member. A member may not nominate more than one person per year.

Nominations must contain name of nominee, current position and address, and current e-mail address, at least three letters of support, a current Curriculum Vitae, and supporting documentation that indicates the nominee's achievements in safety pharmacology (critical in the review of each nominee). Electronic (Word or PDF) or FAXed copy of the nomination should be sent to SPS Headquarters.

The Award
Presentation of the Award will be given at the Annual Meeting of the Society. The recipient will be given a plaque, a cash award, and an invitation to deliver a presentation that may be published with the meeting proceedings. Travel expenses for the recipient to attend the meeting will be paid.

2007 Distinguished Service Award Winner

Professor Tim G Hammond

Professor Tim Hammond is Vice President of Safety Assessment UK with responsibility for all preclinical toxicology conducted for or on behalf of AstraZeneca in the UK. He heads two laboratories, the major one being in Alderley Park, Cheshire with the second in Charnwood, Loughborough, Leicestershire. Professor Hammond has an interest in cardiovascular toxicity associated with pharmaceutical compounds and in particular the preclinical evaluation of compounds with potential to prolong the QT interval of the ECG and induce fatal arrythmia. He chaired the EFPIA/ABPI preclinical working group that looked at the evaluation of QT prolongation, is a member of the ILSI Cardiovascular evaluation group and is an EFPIA delegate on the ICH expert working group for S7B. Professor Hammond is a past President of the British Toxicology Society, and is a member of the Preclinical Drug Safety Advisory Group of the ABPI and EFPIA. Professor Hammond was also a member and co-chair of a working group considering safety pharmacology as part of the Academy of Medical Science Forum considering Better Safety Assessment of Medicinal Products. He is the co-chair of the ILSI Working Party looking at the carcinogenicity of PPAR Agonists. Professor Hammond is a Council member of the British Bioscience Federation and is a Fellow of the Royal College of Pathologists.

Safety & Secondary Pharmacology Past, Present & Future – (Member only access)

The DSA Committee
The President will, in January, appoint a committee of 4, and either Chairs the committee or appoints a chair, making a five-person committee.

The Committee will draft a notice soliciting nominations that will be sent to the membership and posted on the Web site the second week of October.

Nominations are due by January 11. The Committee will review the nominations, have a teleconference in January and make a decision by Feburary 11. The winner will be notified no later than Feburary 21 by letter from the President and/or the Chair of the Committee.